{"name":"Alios Biopharma Inc.","slug":"alios-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"ACH-3102","genericName":"ACH-3102","slug":"ach-3102","indication":"Other","status":"phase_2"},{"name":"ALS-002200","genericName":"ALS-002200","slug":"als-002200","indication":"Other","status":"phase_1"},{"name":"AL-034","genericName":"AL-034","slug":"al-034","indication":"Other","status":"phase_1"},{"name":"AL-794 suspension","genericName":"AL-794 suspension","slug":"al-794-suspension","indication":"Other","status":"phase_1"},{"name":"ALS-008112","genericName":"ALS-008112","slug":"als-008112","indication":"Other","status":"phase_1"},{"name":"ALS-008176","genericName":"ALS-008176","slug":"als-008176","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"ACH-3102","genericName":"ACH-3102","slug":"ach-3102","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALS-002200","genericName":"ALS-002200","slug":"als-002200","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AL-034","genericName":"AL-034","slug":"al-034","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AL-794 suspension","genericName":"AL-794 suspension","slug":"al-794-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALS-008112","genericName":"ALS-008112","slug":"als-008112","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALS-008176","genericName":"ALS-008176","slug":"als-008176","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5DUFk2TWFNSmVvOTFvVVVCYkpUdEdNOUFwTkM1V1hmVkxPQ19JMXZTUnJjQUppMEVITkI2VnR3R2phTjNWYURINjFQQnE3WVVmbUtDWlRzX3hjdHFEWGZRYTNZSFpLUkdGUEhGWnFLY3RXd1NaeVZjR09sOWl3WjQ?oc=5","date":"2024-10-30","type":"pipeline","source":"Bioprocess Online","summary":"How Cidara Got Its Molecule Back - Bioprocess Online","headline":"How Cidara Got Its Molecule Back","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPWFBYM24wMHRqX3ZhTWo3QUVlbEpIU3M4YXRFSURleTFyVmdQU0F3T21yWUVxNzFJLUYzRlNmU2JWMFJENW9YM1RFZWtKS2M4RG9yRE1wYWp2NVRNMjBEckRPWGtRQ2p3aVBMVHVhdzNHUXp6emZ6WmhlbVFPUGRiNWVwdW8tdXNpOWwxd2JLTUhRQW1OR0JqWQ?oc=5","date":"2024-08-31","type":"pipeline","source":"firstonline.info","summary":"Johnson & Johnson stock, JNJ stock quotes on the stock exchange - firstonline.info","headline":"Johnson & Johnson stock, JNJ stock quotes on the stock exchange","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOa08tM3A4MU54aDNTNmhyYVBPcVNTOWNSVWk5dzZMeHp0TnpwRHFvZEtXc1QzaGFETU81TEo0OVRqYmNoNkNTT2dnNjBRM0hnRzhjbDVyaUd3S01LelB0WG0yRk5lQjR0ZEdpaFpsTVp1R3hWdGFxb2lTbjFoemFMa2NwZTVQUEd2MjdTZWJLSlN0ZF9KV09XeVZWOU55SWxQcVB5aGQ1a09CT3d2VlY4dUFqMFFKMmMtSF9iZzE5eGNxQnR2dlY0c042MmJzUHhlTUNNODMySkJGX1g4V1ZMeTk1Umw?oc=5","date":"2024-08-30","type":"pipeline","source":"PR Newswire","summary":"Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by 2030 | DelveInsight - PR Newswire","headline":"Global Anti-Infective Drugs Market is Projected to Cross ~USD 175 Billion by 2030 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQRXFKUEowRDhWa3BSWVhVREhReklUR1BLU2ljMFhXbXAwT2lGczZNaTRLVjJnd1VTOGdocXJ5eUp6QWM2SG1NLWZCSEljdzh5aHcxeHM0UmNzNy1pX29CNlJyeDY0Vmtod1lvY3dlb2tPSVNMXzUzUTI0TEhjdWFMVlNfcUQ4QkdVa2pkQ3RIakRpb1hP?oc=5","date":"2024-01-09","type":"deal","source":"GSK","summary":"GSK enters agreement to acquire Aiolos Bio - GSK","headline":"GSK enters agreement to acquire Aiolos Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOcVZ3QjhsS2JnVnJ1T0JLQk54ZUM5ZlNQbGluV0I3T0ZXbnNkUzN1NzVSSjBWRXkwSEd5UVRpNUh3T3JtdjF3RUY5UGlmUGxmYTRRNVFkVXV2XzVhY1pkcVJaRVFtWUI2UnF6WkRkcktucll0M2RHQmdZQXRTellEUGNDTTA1T3R2bXJkU2hBRzNZZTA?oc=5","date":"2023-03-29","type":"pipeline","source":"BioPharma Dive","summary":"J&J abandons RSV vaccine in major strategy shift - BioPharma Dive","headline":"J&J abandons RSV vaccine in major strategy shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNaFo5SHFhanlHTllMUml1a25LY2VBN09rN3NZSlk4OC1tVzlfdUp3Mll0UnBRMXBEZ3RmRGhIMWo5d3QzcUhlZ2FJTnNndWZlVGU1S1ExN1FRM05BSFFBd244akVpLXFhTmFVaTVRNXBzeURPUTJFWnRyVkVyaTNkeU9VMjVTdw?oc=5","date":"2017-09-11","type":"pipeline","source":"BioPharma Dive","summary":"J&J moves away from hep C due to rival drugmakers’ cures - BioPharma Dive","headline":"J&J moves away from hep C due to rival drugmakers’ cures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE9qaTdlM1hkWDN5ZW56Rm1GejBPcG1nRVpERG56NHRxdkVaWUx3VW5TeXV1dGw0QjRvY1N4OVduZ1VUaFZyNmhSQkU2QnpFZU1nQlROWk80TnM0d1F2bmJublJNN1VBeEFFbXZvTkY5SXpGYVF5emFFZDB2dw?oc=5","date":"2016-10-11","type":"pipeline","source":"Fierce Pharma","summary":"Fierce Women in Biopharma 2016 - Fierce Pharma","headline":"Fierce Women in Biopharma 2016","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQTTlqa292ZGpUT0RtRFdmYVJQWURxLW00dDBPRGY1UEREWEdqem5PRzZPMTBzc1hEcS1fcGdYVmZ3dlVEeEFGdmFWNFJPOEkxQnRqbWpfdmlKa3BXemNONlVBVGJOOW16T0ZEM0dGb2YyZldONkhULUFXbmlEcWRycXpLdGFKanlYWUphQldZSzNkU2dNdlZxNXNGS0ZQOS0wZ2FDU192a0g?oc=5","date":"2013-03-08","type":"pipeline","source":"bizjournals.com","summary":"Drug developer Gilead reaching for a hepatitis C virus cure - bizjournals.com","headline":"Drug developer Gilead reaching for a hepatitis C virus cure","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_2":2,"phase_1":4},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}